Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from natalizumab to Gilenya in relapsing-remitting multiple sclerosis
2013-004616-21Phase 4Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Universitätsklinikum Münster. Primary endpoints: Change in immune function and migratory capacity of immune cells/PBMCs and Change in CD49d expression. Started Feb 2014; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2013-004616-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004616-21.